News

Pfizer announced the FDA approval of TALZENNA® (talazoparib) on October 16, 2018.

Posted on 11.1.2018

Pfizer announced the FDA approval of TALZENNA® (talazoparib) on October 16, 2018. The following information is for your review:

Prescribing Information: click hereRead More

American Society of Clinical Oncology to submit comments on Part B Payment Model Proposal

Posted on 11.1.2018

ASCO shares the Administration’s goal of achieving lower drug costs but is concerned about some aspects of the proposal. ASCO is analyzing the proposal to determine the impact on patient care and practices. The society will respond to the Administration’s … Read More

CMS Takes Action to Modernize Medicare Home Health

Posted on 11.1.2018

On October 31, CMS finalized significant changes to the Home Health Prospective Payment
System (PPS) to strengthen and modernize Medicare. Specifically, CMS made changes to
improve access to solutions via remote patient monitoring technology, updated payments for
home health care … Read More

AstraZeneca announces FDA approval of LUMOXITITM for the treatment of certain adult patients

Posted on 9.18.2018

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has approved LUMOXITITM (moxetumomab pasudotox-tdfk), a first-in-class CD22-directed cytotoxin, for the treatment of adult patients with relapsed or refractory hairy … Read More

FDA Approves Expanded Label for Merck’s KEYTRUDA®

Posted on 8.29.2018

FDA Approves Expanded Label for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy for First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberrations
Approval Based on Results of KEYNOTE-189, Where … Read More

2019 Physician Fee Schedule Proposed Rule

Posted on 8.27.2018
The  2019 Medicare Physician Fee Schedule Proposed Rule with comment period  was placed on display at the Federal Register on July 12, 2018. This proposed rule updates payment policies, payment rates, and other provisions for services furnished under the Medicare
Read More

Opdivo® (nivolumab) Receives FDA Approval for Certain Patients with Previously Treated Small Cell Lung Cancer

Posted on 8.17.2018

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer

(BMS) Aug 17, 2018 – Bristol-Myers Squibb Company today announced that Opdivo (nivolumab) … Read More

XTANDI Approved for Treatment of CRPC

Posted on 7.24.2018

Astellas Pharma US, Inc. and Pfizer Inc. are pleased to announce that XTANDI is now indicated for the treatment of castration-resistant prostate cancer (CRPC) patients.

 … Read More

U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™

Posted on 7.23.2018

U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™
(filgrastim-aafi)
Release Date:
Friday, July 20, 2018 4:24 pm EDT
Terms:
Dateline City:
NEW YORK
NIVESTYM™, a biosimilar to Neupogen ® (filgrastim), is Pfizer’s fourth
biosimilar to be approved by the FDA
NEW YORK–(BUSINESS … Read More

Keytruda RECEIVES FDA APPROVAL for the Treatment of Refractory Relapsed Primary Mediastinal Large B-Cell Lymphoma in Adult and Pediatric Patients

Posted on 6.27.2018

FDA Approved for the Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma in Adult and Pediatric Patients

Merck is pleased to announce that KEYTRUDA® (pembrolizumab) is indicated for the treatment of adult and pediatric patients with refractory Read More